| Identification | Back Directory | [Name]
sodiuM (R)-(Methylsulfonyl)(2-(4-(((trifluoroMethyl)sulfonyl)oxy)phenyl)propanoyl)aMide | [CAS]
865625-56-5 | [Synonyms]
DF2156
DF-2156
DF2156A
DF 2156
DF 2156A
DF-2156A
sodiuM (R)-(Methylsulfonyl)(2-(4-(((trifluoroMethyl)sulfonyl)oxy)phenyl)propanoyl)aMide | [Molecular Formula]
C11H11F3NNaO6S2 | [MDL Number]
MFCD22419381 | [MOL File]
865625-56-5.mol | [Molecular Weight]
397.323 |
| Hazard Information | Back Directory | [Uses]
Ladarixin Sodium is a a dual CXCR1/2 inhibitor. It has therapeutic potential for treating type I diabetes and various melanoma. | [in vivo]
Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure[1].
Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice[1].
Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection[1].
Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts[2]. | Animal Model: | Mice (cigarette smoke-induced exacerbation of Influenza-A infection model)[1] | | Dosage: | 10 mg/kg | | Administration: | P.o. once a day at days 2, 3 and 4 post-infection | | Result: | Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group. |
| [IC 50]
CXCR1; CXCR2 | [storage]
Store at -20°C |
|
|